Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Open-Label Study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects With FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

NCT01565668 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT01565668
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01565668 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Open-Label Study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects With FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Lead sponsor
Daiichi Sankyo
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2012
Completion date
March 31, 2015
Enrollment
76 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, myeloid, acute